Correction to: Drugs & Therapy Perspectives (2019) 35:263–270 https://doi.org/10.1007/s40267-019-00632-w
The article Caplacizumab in acquired thrombotic thrombocytopenic purpura: a profile of its use, written by Hannah A. Blair and Katherine A. Lyseng-Williamson, was originally published Online First without open access. After publication in volume 35, issue 6, pages 263–270, Ablynx, a Sanofi Company requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Ablynx, a Sanofi Company. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Blair, H.A., Lyseng-Williamson, K.A. Correction to: Caplacizumab in acquired thrombotic thrombocytopenic purpura: a profile of its use. Drugs Ther Perspect 35, 459 (2019). https://doi.org/10.1007/s40267-019-00654-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-019-00654-4